-

05:23:20 PM

Latest IONS Stock Market News

IONS - Ionis Pharmaceuticals Inc

06/14/21 4:05 PM

Nasdaq : IONS

Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23 rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his

RHEA-AI

positive

06/10/21 6:05 PM

Nasdaq : IONS

Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual

RHEA-AI

neutral

06/02/21 7:59 PM

Nasdaq : IONS

Ionis announces changes to its board of directors at annual meeting of stockholders

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board. As previously announced, Ionis

RHEA-AI

very positive

05/26/21 7:05 AM

Nasdaq : IONS

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences:William Blair 41 st Annual Growth Stock Conference on Tuesday, June 1, 2021 Goldman Sachs 42 nd

RHEA-AI

neutral

05/06/21 7:05 AM

Nasdaq : IONS

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following investor conferences:Bank of America Healthcare Conference on Wednesday, May 12, 2021 RBC Capital Markets Global

RHEA-AI

neutral

05/05/21 4:05 PM

Nasdaq : IONS

Ionis to host 2021 virtual annual meeting of stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2021 virtual Annual Meeting of Stockholders followed by a general corporate update on Wednesday, June 2, 2021. This event will be webcast live on the internet in

RHEA-AI

neutral

05/05/21 7:00 AM

Nasdaq : IONS

Ionis reports first quarter 2021 financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights."In the first quarter, we took important steps to maximize the value of our wholly owned pipeline. We recently

RHEA-AI

neutral

04/21/21 7:05 AM

Nasdaq : IONS

Ionis to hold first quarter 2021 financial results webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and report on pipeline and business

RHEA-AI

neutral

04/20/21 7:05 AM

Nasdaq : IONS

Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder. Alexander disease patients experience progressive

RHEA-AI

neutral

04/08/21 7:05 AM

Nasdaq : IONS

Ionis prices private placement of convertible senior notes

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified institutional buyers

RHEA-AI

neutral

1 2 3 4 5 6 Next

IONS Data

industryPharmaceutical Preparation Manufacturing
websitewww.ionispharma.com
ceoBrett Monia
security nameIonis Pharmaceuticals Inc
issue typecs
sectorManufacturing
sic code2834
employees
tagsHealth Technology,Biotechnology,Manufacturing,Pharmaceutical Preparation Manufacturing
address2855 Gazelle Ct
address2
stateCalifornia
cityCarlsbad
zip92010-6670
countryUS
phone17609319200

IONS Description:

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.